SynBiotic Builds North American Ties to Secure Overseas Funding

DÜSSELDORF – SynBiotic SE, a publicly traded European company focused on medical Сannabis and industrial hemp, has formed alliances with several North American advisory firms to broaden its reach among global investors. The move aims to support the firm’s acquisition-driven growth plan by tapping into fresh capital sources beyond Europe.

Announced recently, the partnerships include Hyde Advisory & Investments, based in Toronto, which specializes in investor outreach and deal structuring in the Cannabis field. Led by David Hyde, the group offers guidance on fundraising, due diligence, and risk management. SynBiotic also linked up with U.S. attorney Bob Hoban, known for his work in Cannabis law and market entry strategies, to address cross-border regulations.

Additional collaborators encompass the Global Cannabis Network Collective, founded by Chris Day, which connects top executives for deal-making and insights; The Talman Group, a European network of Cannabis investors and leaders; and Golden Eagle Partners, a U.S. firm with experience in international transactions. As part of the initiative, SynBiotic’s chief executive, Daniel Kruse, appeared in a webinar hosted by Golden Eagle Partners this month, discussing the company’s strategy with managing director David Traylor.

Kruse described the effort as a step toward leading industry advancements, stating in a release that the collaborations would help shape future developments. The company, which oversees a diversified portfolio spanning research to retail, positions itself to minimize risks through broad operations in Europe while eyeing international opportunities.

Financial details of the partnerships remain undisclosed, and SynBiotic plans to release its half-year results next month. The stock’s performance reflects cautious optimism, though broader market factors like regulatory shifts in Germany and the U.S. could influence outcomes.

From an industry perspective, these cross-continental links highlight a practical response to funding challenges in the Cannabis sector. While they could provide SynBiotic with an edge in scaling operations, the real test lies in converting networks into tangible deals amid ongoing global policy uncertainties. Highly Capitalized Network-HCN will watch closely for execution in the coming quarters.